Middle East & Africa Oligonucleotide Therapeutics Market Size & Outlook

The oligonucleotide therapeutics market in Middle East & Africa is expected to reach a projected revenue of US$ 879.4 million by 2033. A compound annual growth rate of 21.2% is expected of Middle East & Africa oligonucleotide therapeutics market from 2026 to 2033.
Revenue, 2025 (US$M)
$189.4
Forecast, 2033 (US$M)
$879.4
CAGR, 2026 - 2033
21.2%
Report Coverage
Middle East & Africa

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Middle East & Africa oligonucleotide therapeutics market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

MEA oligonucleotide therapeutics market highlights

  • The MEA oligonucleotide therapeutics market generated a revenue of USD 189.4 million in 2025.
  • The market is expected to grow at a CAGR of 21.2% from 2026 to 2033.
  • In terms of segment, antisense oligonucleotides (asos) was the largest revenue generating oligonucleotide class in 2025.
  • MicroRNA (miRNA) is the most lucrative oligonucleotide class segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2026 to 2033.


MEA data book summary

Market revenue in 2025USD 189.4 million
Market revenue in 2033USD 879.4 million
Growth rate21.2% (CAGR from 2026 to 2033)
Largest segmentAntisense oligonucleotides (asos)
Fastest growing segmentMicroRNA (miRNA)
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationAntisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Aptamers, MicroRNA (miRNA), CpG Oligonucleotides, Other Oligonucleotide Therapeutics


Other key industry trends

  • In terms of revenue, MEA region accounted for 2.6% of the global oligonucleotide therapeutics market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 7,914.3 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Oligonucleotide Therapeutics Market Companies

Name Profile # Employees HQ Website
Wave Life Sciences View profile 251-500 Boston, Massachusetts, United States, North America http://wavelifesciences.com
Sarepta Therapeutics Inc View profile 1314 215 First Street, Suite 415, Cambridge, MA, United States, 02142 https://www.sarepta.com
Silence Therapeutics PLC View profile 109 72 Hammersmith Road, London, United Kingdom, W14 8TH https://www.silence-therapeutics.com
Arrowhead Pharmaceuticals Inc View profile 525 177 E. Colorado Boulevard, Suite 700, Pasadena, CA, United States, 91105 https://www.arrowheadpharma.com
Alnylam Pharmaceuticals Inc View profile 2100 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 https://www.alnylam.com
Ionis Pharmaceuticals Inc View profile 927 2855 Gazelle Court, Carlsbad, CA, United States, 92010 https://www.ionispharma.com
Biogen Inc View profile 7570 225 Binney Street, Cambridge, MA, United States, 02142 https://www.biogen.com
Roche View profile 10001+ Basel, Basel-Stadt, Switzerland, Europe http://www.roche.com
Nitto Denko Corp View profile 28193 4-20, Ofuka-Cho, 33rd Floor, Grand Front Osaka, Kita-Ku, Osaka, Japan, 530-0011 http://www.nitto.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com

Middle East & Africa oligonucleotide therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oligonucleotide therapeutics market will help companies and investors design strategic landscapes.


Antisense oligonucleotides (asos) was the largest segment with a revenue share of 55.12% in 2025. Horizon Databook has segmented the Middle East & Africa oligonucleotide therapeutics market based on antisense oligonucleotides (asos), small interfering rna (sirna), aptamers, microrna (mirna), cpg oligonucleotides, other oligonucleotide therapeutics covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to Middle East & Africa oligonucleotide therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa oligonucleotide therapeutics market databook

  • Our clientele includes a mix of oligonucleotide therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa oligonucleotide therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa oligonucleotide therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

MEA oligonucleotide therapeutics market size, by country, 2021-2033 (US$M)

Middle East & Africa Oligonucleotide Therapeutics Market Outlook Share, 2025 & 2033 (US$M)

MEA oligonucleotide therapeutics market size, by country, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online